Geenen LW, et al. - In this prospective cohort study, researchers examined consecutive patients with adult congenital heart disease (ACHD) (n=602), to determine the release of soluble suppression of tumourigenicity-2 (sST2) as well as its link with cardiovascular events in this patient population. In 590 (98%) patients (median age 33 years, 42% women), sST2 was measured in this study. A significant association of sST2 with the primary endpoint (all-cause mortality, heart failure, hospitalisation, arrhythmia, thromboembolic events or cardiac interventions) was found when adjusted for age, sex, creatinine and N  terminal pro-B type brain natriuretic peptide (NT-proBNP). When adjusted for clinical variables and NT-proBNP, this link negated. A link between sST2 and the primary endpoint was evident in women but not in men, in sex-specific analysis. Overall, sST2 can serve as a promising new biomarker in patients with ACHD, particularly in complex ACHD and women.